Results of this study showed no improvement in the rate of 30-day hospital readmission for patients with cancer undergoing pancreatectomy between 2005 and 2011.
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
The US FDA has approved olaparib for the maintenance treatment of some adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma.